AstraZeneca's IMFINZI-Tarlatamab Combo Shows Breakthrough Survival Gains in Small Cell Lung Cancer
Event summary
- IMFINZI (durvalumab) plus Amgen’s tarlatamab demonstrated statistically significant improvements in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer (ES-SCLC).
- The DeLLphi-305 Phase III trial included 563 patients who completed IMFINZI-based induction treatment and were randomized to receive either the combination therapy or IMFINZI alone.
- The safety profile of the combination was consistent with the known safety profiles of the individual treatments, with no new safety signals identified.
- Results will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
The big picture
AstraZeneca's positive results from the DeLLphi-305 trial represent a significant advancement in the treatment of ES-SCLC, a highly aggressive form of lung cancer with limited treatment options. The combination of IMFINZI and tarlatamab could redefine the standard of care, potentially extending survival for patients who previously had poor prognosis. This development underscores the growing importance of combination immunotherapies in oncology, as well as AstraZeneca's leadership in lung cancer treatment.
What we're watching
- Regulatory Approval
- The pace at which global regulatory authorities will review and approve the combination therapy for ES-SCLC.
- Market Adoption
- How quickly oncologists will adopt the IMFINZI-tarlatamab combination as a new standard of care for ES-SCLC.
- Competitive Dynamics
- Whether this breakthrough will pressure competitors to accelerate their own combination therapy developments in oncology.
Related topics